Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06047379
Title	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Neonc Technologies, Inc.
Indications	squamous cell carcinoma melanoma lung small cell carcinoma renal cell carcinoma Merkel cell carcinoma colorectal cancer astrocytoma, IDH-mutant, grade 3 astrocytoma, IDH-mutant, grade 2 cervical cancer Advanced Solid Tumor esophagus squamous cell carcinoma lung non-small cell carcinoma stomach cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma esophageal cancer astrocytoma, IDH-mutant, grade 4 transitional cell carcinoma IDH-wildtype glioblastoma
Therapies	NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab
Age Groups:	senior \| adult
Covered Countries	USA